

StarkAge Therapeutics: Appointment of Dr. Benjamin LeCalvé as Chief Executive Officer (CEO) of StarkAge Therapeutics

Paris, October 11, 2024 – StarkAge Therapeutics, a biotechnology company specializing in therapies targeting cellular senescence, today announced the appointment of Dr. Benjamin LeCalvé as Chief Executive Officer (CEO), effective October 1, 2024. **Dr. LeCalvé, who previously served as Chief Scientific Officer (CSO), succeeds Dr. Thierry Mathieu**, the company's founder and president, who has led the company since its inception. The appointment of Dr. LeCalvé aligns with StarkAge Therapeutics' strategy to strengthen its leadership for the next phase of development, particularly in preparation for the fundraising round beginning in November 2024.

Dr. Benjamin LeCalvé, a recognized expert in senescence and cancer research, joined StarkAge Therapeutics in 2022 and has played a key role in shaping the company's scientific strategy and repositioning its drug candidate toward an ADC (Antibody Drug Conjugate) model. He also spearheaded the formation of the Scientific Advisory Board (SAB), which brings together global experts in senescence and aging-related cancers, as well as the Advisory Board, which advises the leadership team on the company's overall strategy.

"It is an honor to take on this role at such a pivotal moment for StarkAge Therapeutics. We have a unique opportunity to transform senescence research into real treatments to fight cancer and other aging-related diseases. I look forward to working with our teams and partners to accelerate the development of our drug candidates and prepare for our upcoming fundraising round," said **Dr. Benjamin LeCalvé, CEO of StarkAge Therapeutics.**

Under the leadership of Dr. Thierry Mathieu, StarkAge Therapeutics has distinguished itself through its innovative approach to therapies targeting senescent cells, particularly in cancer treatment. **Dr. Mathieu will continue to serve as the company's President and will support the strategic development of the business.**

About StarkAge Therapeutics

StarkAge Therapeutics is a biotechnology company specializing in the research and development of targeted therapies against cellular senescence, a process involved in aging and many chronic diseases, including cancer. The company is recognized for its pioneering approach to developing new drug candidates aimed at extending healthy lifespan. In 2021, associated to the DeepTech program operated by BpiFrance, the company received a staggered grant of €2m.

Press Contact :
Thierry MATHIEU
thierry.mathieu@starkage.com
Tel : 0033 6 77 17 72 27